Regeneron Pharmaceuticals, Inc.

-2.16 (-0.39%)
Regulatory, Earnings Announcements

Sanofi's Phase 3 Trial Of Libtayo (Cemiplimab) Stopped Early For Positive Result On Overall Survival

Published: 03/15/2021 06:15 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival.
Fourth Cancer Type Where Libtayo Has Positive Pivotal Data; Regulatory Submissions Planned in 2021.
This Trial Will Be Stopped Early Based on a Unanimous Recommendation by Independent Data Monitoring Committee (idmc), and Data Will Form Basis of Regulatory Submissions in 2021.
Data Contribute to Growing Evidence Demonstrating Significant Potential of Libtayo to Treat a Spectrum of Difficult-to-treat Cancers.
Revenue is expected to be $2.7 Billion
Adjusted EPS is expected to be $9.95

Next Quarter Revenue Guidance is expected to be $4.91 Billion
Next Quarter EPS Guidance is expected to be $15.09

More details on our Analysts Page.